Market Cap
$859.1M
RIGL
RIGEL PHARMACEUTICALS INC
$46.50 ▼ -1.00%
Prev close $46.97Market cap$859.1M
ConsensusBuy
12-mo target$63.00 (+35.5%)
▲ Bullish
Analyst conviction 7/10
High Impact Filing (7/10)15 New Institutional Positions20 Institutional Exits Biotech & Drug Discovery
Snapshot
The big-picture read on RIGL right now — valuation, ownership and activity at a glance.
Cap Size
Small Cap
Analyst Consensus
Strong Buy (73%)
Inst. Holders
50 funds
Inst. Value
$391.4M
Inst. Activity
15 buys / 20 sells
Insider Activity
$0.00 buy / $305.9K sell
Insider Net $
-$305.9K
SEC Reports
8
Price chart 30d -5.9%
Daily candles (open–high–low–close) with volume. Green = up day, red = down day.
No data for this timeframe.
Vol
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 2, 2026 other
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nas
Sep 2, 2026 Insider
Schorno Dean L acquired via exercise 694 shares
EVP & Chief Financial Officer @ $12.70 ($8.8K)
Sep 2, 2026 Insider
Schorno Dean L acquired via exercise 2,000 shares
EVP & Chief Financial Officer @ $24.20 ($48.4K)
Sep 2, 2026 Insider
Aug 4, 2026 SEC Schorno Dean L acquired via exercise 620 shares
EVP & Chief Financial Officer @ $18.70 ($11.6K)
Rigel Pharmaceuticals reported Q2 2026 revenue of $78.7M (net product sales $67.0M, +14% YoY) and EPS of $0.88, missing
8-K — Impact 6/10
Jun 30, 2026 Inst.
AMERICAN CENTURY COMPANIES INC — ADD
741,718 shares ($29.0M)
Jun 30, 2026 Inst.
Jun 17, 2026 SEC MARSHALL WACE, LLP — TRIM
367,393 shares ($14.4M)
Rigel Pharmaceuticals completed its previously announced exclusive global license agreement with Arvinas and Pfizer for
8-K — Impact 4/10
Analyst ratings buy % +9.0%
How Wall Street rates the stock today, and the latest firm-by-firm actions.
73% rate it Buy or better · 11 analysts
Recent analyst actions
| Date | Firm | Action | Rating | Firm rating |
|---|---|---|---|---|
| Aug 17, 2026 | Piper Sandler | MAINTAIN | Neutral | 54% |
| Aug 14, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | 43% |
| Jun 2, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 27, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | 43% |
| May 13, 2026 | Citigroup | MAINTAIN | Buy | 55% |
| May 7, 2026 | Citigroup | MAINTAIN | Buy | 55% |
Monthly consensus history
| Period | Str. Buy | Buy | Hold | Sell | Str. Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Sep 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Aug 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Jul 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| Jun 1, 2026 | 4 | 4 | 3 | 0 | 0 | 73% | |
| May 1, 2026 | 4 | 4 | 4 | 0 | 0 | 67% | |
| Apr 1, 2026 | 4 | 4 | 4 | 0 | 0 | 67% | |
| Mar 1, 2026 | 4 | 4 | 4 | 0 | 0 | 67% | |
| Feb 1, 2026 | 4 | 4 | 4 | 0 | 0 | 67% |
Price targets
Where 5 covering analysts think RIGL trades over the next 12 months.
$63.00 +35.5% upside Strong Buy
Current$46.50 Low$43.00 Median$55.00 High$85.00 5 analysts
$43.00$85.00
Analyst rating None as of Oct 2, 2026
Reports & filings
AI-scored summaries of recent SEC filings and press releases, with sentiment and impact.
8 SEC filing reports analyzed · 1 bullish, 2 bearish, 1 mixed, 4 neutral · avg impact 4.8/10.
MIXED8-K6/10
Rigel Pharmaceuticals reported Q2 2026 revenue of $78.7M (net product sales $67.0M, +14% YoY) and EP
Aug 4, 2026
NEUTRAL8-K4/10
Rigel Pharmaceuticals completed its previously announced exclusive global license agreement with Arv
Jun 17, 2026
NEUTRALINST-CLUSTER3/10
Mixed institutional cluster for RIGL in Q3 2025: six funds (mostly passive + quants) added $21.8M, w
Jun 11, 2026
NEUTRAL8-K2/10
Rigel Pharmaceuticals filed an 8-K reporting the results of its 2026 Annual Meeting of Stockholders.
May 20, 2026
Upcoming & catalyst events
Scheduled dates plus disclosed catalysts — earnings, dividends, enforcement, FDA and clinical-trial events. Colored dot = impact.
Oct 2, 2026
other
Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Oct. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. ("Rigel") (Nasdaq: RIGL) today announced that it has granted awa
Sep 2, 2026
other
Rigel to Participate in Upcoming September Investor Conferences
SOUTH SAN FRANCISCO, Calif., Sept. 2, 2026 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focuse
Aug 13, 2026
other
Rigel Announces Availability of VEPPANU™ (vepdegestrant) for Patients with ER+/HER2-, ESR1-Mutated Advanced or Metastatic Breast Cancer
VEPPANU is the first and only FDA-approved PROTAC and has the potential to become an important new treatment option for adult patients with 2L+ ER+/HE
Aug 3, 2026
earnings_calendar
RIGL Q2 2026 Earnings Scheduled — 2026-08-03
Jul 8, 2026
ftd
FTD: RIGL — 12,546 shares ($0.5M) failed to deliver
Settlement: 20260708, Price: $42.56, FTD Value: $533,957.76, RIGEL PHARMACEUTICALS INC COM
Earnings estimates
Forecast earnings per share and revenue by period — and whether estimates are rising.
| Period | EPS Est. | Range | Growth | 30d Rev | Up/Dn | Revenue | # |
|---|---|---|---|---|---|---|---|
| Current Q | $0.96 | $0.77–$1.07 | -34.0% | +8.7% | 0↑ 4↓ | $0.1B | 4 |
| Next Q | $1.04 | $0.46–$1.49 | -7.2% | +3.2% | 1↑ 2↓ | $0.1B | 4 |
| Current FY | $3.54 | $2.55–$4.61 | -44.9% | +3.3% | 1↑ 3↓ | $0.3B | 4 |
| Next FY | $4.94 | $2.87–$7.32 | 39.4% | +12.4% | 2↑ 2↓ | $0.4B | 4 |
Current-quarter EPS estimate — revision history
| When | EPS estimate | Change vs now |
|---|---|---|
| Current | $0.964 | — |
| 7d ago | $0.964 | — |
| 30d ago | $0.886 | +0.077 |
| 60d ago | $1.224 | -0.261 |
| 90d ago | $1.274 | -0.311 |
Institutional ownership
Which big funds own RIGL (from quarterly 13F filings) and who is adding or trimming.
50 institutional holders with $391.4M total value (10,006,367 shares) as of 2026-Q2. Top holders: BlackRock,, STATE, VANGUARD. Net selling activity: 20 institutions trimmed/exited vs 15 added.
Top holders — 2026-Q2
| Fund | Shares | Value | % Tracked | Last move |
|---|---|---|---|---|
| BlackRock, Inc. | 1,939,818 | $75.9M | 19.4% | — |
| STATE STREET CORP | 1,039,994 | $40.7M | 10.4% | — |
| VANGUARD CAPITAL MANAGEMENT LLC | 785,107 | $30.7M | 7.8% | — |
| AMERICAN CENTURY COMPANIES INC | 741,718 | $29.0M | 7.4% | ADD +36.2% |
| D. E. Shaw & Co., Inc. | 542,539 | $21.2M | 5.4% | — |
| GEODE CAPITAL MANAGEMENT, LLC | 483,175 | $18.9M | 4.8% | — |
| MARSHALL WACE, LLP | 367,393 | $14.4M | 3.7% | TRIM -38.6% |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 233,728 | $9.1M | 2.3% | ADD +58.4% |
| DIMENSIONAL FUND ADVISORS LP | 227,951 | $8.9M | 2.3% | TRIM -39.9% |
| GOLDMAN SACHS GROUP INC | 226,780 | $8.9M | 2.3% | TRIM -48.4% |
Recent position changes
| Fund | Action | Prev | Current | Change | Value |
|---|---|---|---|---|---|
| AMERICAN CENTURY COMPANIES INC | ADD | 544,431 | 741,718 | +36.2% | $29.0M |
| MARSHALL WACE, LLP | TRIM | 598,378 | 367,393 | -38.6% | $14.4M |
| VANGUARD PORTFOLIO MANAGEMENT LLC | ADD | 147,535 | 233,728 | +58.4% | $9.1M |
| DIMENSIONAL FUND ADVISORS LP | TRIM | 379,541 | 227,951 | -39.9% | $8.9M |
| GOLDMAN SACHS GROUP INC | TRIM | 439,101 | 226,780 | -48.4% | $8.9M |
| MORGAN STANLEY | ADD | 98,868 | 186,049 | +88.2% | $7.3M |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 338,441 | 145,846 | -56.9% | $5.7M |
| Nuveen, LLC | TRIM | 337,427 | 123,961 | -63.3% | $4.8M |
| UBS Group AG | DOUBLED | 50,076 | 122,954 | +145.5% | $4.8M |
| MILLENNIUM MANAGEMENT LLC | TRIM | 264,410 | 93,689 | -64.6% | $3.7M |
Insider activity
Buying and selling by company executives and directors (SEC Form 4).
12 insiders, 46 transactions. Net -$305.9K — $0.00 bought, $305.9K sold.
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Sep 2, 2026 | Schorno Dean L | EVP & Chief Financial Officer | EXERCISE | 694 | $12.70 | $8.8K |
| Sep 2, 2026 | Schorno Dean L | EVP & Chief Financial Officer | EXERCISE | 2,000 | $24.20 | $48.4K |
| Sep 2, 2026 | Schorno Dean L | EVP & Chief Financial Officer | EXERCISE | 620 | $18.70 | $11.6K |
| Sep 2, 2026 | Schorno Dean L | EVP & Chief Financial Officer | EXERCISE | 1,286 | $24.20 | $31.1K |
| Sep 1, 2026 | Furey Raymond J. | EVP, GC, CCO & Corp Sec | TAX W/H | 877 | $47.50 | $41.7K |
| Sep 1, 2026 | Santos David A | EVP, Chief Commercial Officer | TAX W/H | 874 | $47.50 | $41.5K |
| Sep 1, 2026 | RODRIGUEZ RAUL R | CEO, President | TAX W/H | 2,424 | $47.50 | $115.1K |
| Sep 1, 2026 | Schorno Dean L | EVP & Chief Financial Officer | TAX W/H | 928 | $47.50 | $44.1K |
| Jul 8, 2026 | HANNAH ALISON L. | EVP, Chief Medical Officer | AWARD | 24,400 | — | — |
| Jun 22, 2026 | Ali-Jackson Kamil | Director | SELL | 2,500 | $35.00 | $87.5K |
Short interest & halts
FINRA semi-monthly short positions, Reg SHO threshold status, and recent trading halts for RIGL.
Shares short
3,191,811
Settlement Sep 15, 2026
Change vs prior
+0.3%
Semi-monthly cycle
Days to cover
15.8
At avg daily volume
Of shares outstanding
≈17.1%
Estimate — not % of float
All RIGL filing & press-release reports (8)
- 8-K reportAug 4, 2026
- 8-K reportJun 17, 2026
- INST-CLUSTER reportJun 11, 2026
- 8-K reportMay 20, 2026
- 8-K reportMay 12, 2026
- 8-K reportMay 5, 2026
- 8-K reportApr 21, 2026
- DEFA14A reportApr 3, 2026